Tetsuya Mitsudomi

61.8k citations

529 papers · 36.6k indexed · 13 hit papers · h-index 92

Pulmonary and Respiratory Medicine top 0.01%
Oncology top 0.02%
Molecular Biology top 0.1%
Cancer Research top 0.05%
Radiology, Nuclear Medicine and Imaging top 0.2%

Co-authors: Yasushi Yatabe Takashi Takahashi Takayuki Kosaka Hideki Endoh Kenichi Suda Toyoaki Hida Hiroyuki Kuwano Hirotaka Osada
Topics: Lung Cancer Treatments and Mutations (344 papers)Lung Cancer Diagnosis and Treatment (138 papers)Lung Cancer Research Studies (107 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Journals: Science New England Journal of Medicine The Lancet
Partner nations: Japan United States United Kingdom

In The Last Decade

Tetsuya Mitsudomi

508 papers receiving 35.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival

2004 1.9k citations Junichi Takamizawa, Hiroyuki Konishi et al. Cancer Research profile →
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

2004 1.0k citations Takayuki Kosaka, Yasushi Yatabe et al. Cancer Research profile →
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

2010 915 citations Yasushi Yatabe, Tetsuya Mitsudomi et al. profile →
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 830 citations Tetsuya Mitsudomi, Takayuki Kosaka et al. Journal of Clinical Oncology profile →
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

2022 764 citations Morihito Okada, Masahiro Tsuboi et al. profile →
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

1998 718 citations Toyoaki Hida, Yasushi Yatabe et al. profile →
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

2008 513 citations Seiji Yano, Wei Wang et al. Cancer Research profile →
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

2016 502 citations Toyoaki Hida, Helen Mann et al. profile →
A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)

2011 464 citations Tetsuya Mitsudomi, Masahiro Tsuboi et al. profile →
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

2019 310 citations Morihito Okada, Masahiro Tsuboi et al. profile →
A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer

2020 198 citations Ichiro Yoshino, Masahiro Tsuboi et al. profile →
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations Kenichi Suda, Toshio Fujino et al. profile →

Peers

Countries citing papers authored by Tetsuya Mitsudomi

Since Specialization

Citations

This map shows the geographic impact of Tetsuya Mitsudomi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsuya Mitsudomi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsuya Mitsudomi more than expected).

Fields of papers citing papers by Tetsuya Mitsudomi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsuya Mitsudomi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsuya Mitsudomi. The network helps show where Tetsuya Mitsudomi may publish in the future.

Co-authorship network of co-authors of Tetsuya Mitsudomi

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsuya Mitsudomi. A scholar is included among the top collaborators of Tetsuya Mitsudomi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsuya Mitsudomi. Tetsuya Mitsudomi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study 2025 ·Cells ·(unknown),Kenichi Suda,Akira Hamada,Toshio Fujino,Keiko Obata,Yoshihisa Kobayashi,K. Sakai,(unknown),Shuta Ohara,Masaoki Ito,Junichi Soh,Kazuto Nishio,Tetsuya Mitsudomi,Yasuhiro Tsutani	0
2	Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816. 2024 ·Journal of Clinical Oncology ·Jonathan Spicer,Nicolas Girard,Mariano Provencio,Changli Wang,Tetsuya Mitsudomi,Mark M. Awad,Everett E. Vokes,Janis M. Taube,Lorena Lupinacci,Gene Saylors,Fumihiro Tanaka,Moïshe Liberman,Sung Yong Lee,Aurelia Alexandru,M. D’Arcangelo,Phuong Tran,Javed Mahmood,(unknown),(unknown),Patrick M. Forde	25
3	Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study 2024 ·Biomedicines ·(unknown),Kenichi Suda,Akira Hamada,(unknown),Shuta Ohara,Masaoki Ito,Junichi Soh,Tetsuya Mitsudomi,Yasuhiro Tsutani	6
4	Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC 2023 ·Cancer Research ·John V. Heymach,David H. Harpole,Tetsuya Mitsudomi,Janis M. Taube,Gabriella Gálffy,Maximilian J. Hochmair,Thomas Winder,Р. А. Зуков,Gabriel Garbaos,Shugeng Gao,Hiroaki Kuroda,Jian You,Kang‐Yun Lee,Lorenzo Antonuzzo,Mike Aperghis,Gary J. Doherty,Helen Mann,Tamer M. Fouad,Martin Reck	55
5	Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer 2023 ·Journal of Clinical Oncology ·Hirotsugu Kenmotsu,Nobuyuki Yamamoto,Toshihiro Misumi,Kiyotaka Yoh,Haruhiro Saito,Shunichi Sugawara,Koji Yamazaki,Kazuhiko Nakagawa,Kenji Sugio,Takashi Seto,Shinichi Toyooka,Hiroshi Date,Tetsuya Mitsudomi,(unknown),Kohei Yokoi,Hideo Saka,Hiroaki Okamoto,Yuichi Takiguchi,Toshiaki Takahashi,Masahiro Tsuboi	8
6	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L) 2021 ·Clinical Lung Cancer ·Akira Hamada,Junichi Soh,Akito Hata,Kiyoshi Nakamatsu,Mototsugu Shimokawa,Yasushi Yatabe,Hiroyuki Oizumi,Masahiro Tsuboi,Hidehito Horinouchi,Ichiro Yoshino,Masayuki Tanahashi,Shinichi Toyooka,Morihito Okada,Hiroyasu Yokomise,Motohiro Yamashita,Yasumasa Nishimura,Nobuyuki Yamamoto,Kazuhiko Nakagawa,Tetsuya Mitsudomi	12
7	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer 2018 ·Molecular Cancer Therapeutics ·Kenichi Suda,Isao Murakami,Hui Yu,Jihye Kim,Aik Choon Tan,Hiroshi Mizuuchi,Leslie Rozeboom,Kim Ellison,Christopher J. Rivard,Tetsuya Mitsudomi,Fred R. Hirsch	39
8	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer 2016 ·Molecular Cancer Therapeutics ·Yoshihisa Kobayashi,Koichi Azuma,Hiroki Nagai,Young Hak Kim,Yosuke Togashi,(unknown),Masato Chiba,Masaki Shimoji,Katsuaki Sato,Kenji Tomizawa,Toshiki Takemoto,Kazuto Nishio,Tetsuya Mitsudomi	57
9	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2 2016 ·Clinical Cancer Research ·Masato Terashima,Yosuke Togashi,Katsuaki Sato,Hiroshi Mizuuchi,Kazuko Sakai,Kenichi Suda,Yu Nakamura,Eri Banno,Hidetoshi Hayashi,Marco A. De Velasco,Yoshihiko Fujita,Shuta Tomida,Tetsuya Mitsudomi,Kazuto Nishio	15
10	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs 2015 ·Clinical Cancer Research ·Yoshihisa Kobayashi,Yosuke Togashi,Yasushi Yatabe,Hiroshi Mizuuchi,Park Jangchul,(unknown),Masaki Shimoji,Katsuaki Sato,Kenichi Suda,Kenji Tomizawa,(unknown),Toyoaki Hida,Kazuto Nishio,Tetsuya Mitsudomi	164
11	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer 2012 ·Molecular Cancer Therapeutics ·Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Shigeki Nanjo,Daisuke Ishikawa,Takako Sano,Kenji Kita,Takahiro Nakamura,Kunio Matsumoto,Kenichi Suda,Tetsuya Mitsudomi,Yoshitaka Sekido,Toshimitsu Uenaka,Seiji Yano	74
12	Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stress–Response Pathways 2010 ·Cancer Research ·Kiyoshi Yanagisawa,Hiroyuki Konishi,Chinatsu Arima,Shuta Tomida,Toshiyuki Takeuchi,Yukako Shimada,Yasushi Yatabe,Tetsuya Mitsudomi,Hirotaka Osada,Takashi Takahashi	22
13	Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer 2010 ·Clinical Cancer Research ·Kenichi Suda,Isao Murakami,Tatsuya Katayama,Kenji Tomizawa,Hirotaka Osada,Yoshitaka Sekido,Yoshihiko Maehara,Yasushi Yatabe,Tetsuya Mitsudomi	170
14	Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses 2009 ·Cancer Research ·Hiromichi Ebi,Shuta Tomida,Toshiyuki Takeuchi,Chinatsu Arima,Takahiko Sato,Tetsuya Mitsudomi,Yasushi Yatabe,Hirotaka Osada,Takashi Takahashi	31
15	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutationsbreakdown → 2008 ·Cancer Research ·Seiji Yano,Wei Wang,Qi Li,Kunio Matsumoto,(unknown),Takahiro Nakamura,Hirokazu Ogino,Soji Kakiuchi,Masaki Hanibuchi,Yasuhiko Nishioka,Hisanori Uehara,Tetsuya Mitsudomi,Yasushi Yatabe,Toshikazu Nakamura,Saburo Sone	513
16	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signalingbreakdown → 2007 ·Science ·Jeffrey A. Engelman,Kreshnik Zejnullahu,Tetsuya Mitsudomi,Youngchul Song,Courtney Hyland,Joon Oh Park,Neal I. Lindeman,(unknown),Xiao‐Jun Zhao,James G. Christensen,Takayuki Kosaka,Alison J. Holmes,Andrew M. Rogers,Federico Cappuzzo,Tony Mok,Charles Lee,Bruce E. Johnson,Lewis C. Cantley,Pasi A. Jänne	3570
17	Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1 2007 ·Cancer Research ·Hisaaki Tanaka,Kiyoshi Yanagisawa,Keiko Shinjo,Ayumu Taguchi,Ken Maeno,Shuta Tomida,Yukako Shimada,Hirotaka Osada,Takayuki Kosaka,Hideo Matsubara,Tetsuya Mitsudomi,Yoshitaka Sekido,Mitsune Tanimoto,Yasushi Yatabe,Takashi Takahashi	165
18	Reduced Expression of the *let-7* MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survivalbreakdown → 2004 ·Cancer Research ·Junichi Takamizawa,Hiroyuki Konishi,Kiyoshi Yanagisawa,Shuta Tomida,Hirotaka Osada,Hideki Endoh,(unknown),Yasushi Yatabe,Masato Nagino,Yuji Nimura,Tetsuya Mitsudomi,Takashi Takahashi	1938
19	p53 Immunostaining Positivity Is Associated With Reduced Survival and Is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer 1994 ·CHEST Journal ·David P. Carbone,Tetsuya Mitsudomi,Itsuo Chiba,Steven Piantadosi,Valerie W. Rusch,Jan A. Nowak,Donald D. McIntire,Dennis J. Slamon,Adi F. Gazdar,J D Minna	92
20	Absence of hereditary p53 mutations in 10 familial leukemia pedigrees. 1992 ·Journal of Clinical Investigation ·Carolyn A. Felix,D D’Amico,Tetsuya Mitsudomi,Marion M. Nau,(unknown),Joseph F. Fraumeni,Diane E. Cole,(unknown),Gregory H. Reaman,J. Whang‐Peng	34

About Tetsuya Mitsudomi

Tetsuya Mitsudomi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 529 papers that have together received 36.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (344 papers), Lung Cancer Diagnosis and Treatment (138 papers) and Lung Cancer Research Studies (107 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (22.7k citations), Oncology (18.1k citations) and Cancer Research (8.5k citations). Tetsuya Mitsudomi has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yasushi Yatabe, Takashi Takahashi, Takayuki Kosaka, Hideki Endoh, Kenichi Suda, Toyoaki Hida, Hiroyuki Kuwano, Hirotaka Osada, Yoshihisa Kobayashi and Shuta Tomida. Their work appears in journals such as Science, New England Journal of Medicine and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact